Choose a language and wait for the translated text.
Under the agreement, the chinese drugmaker is entitled to receive up to $123 million in upfront, development and regulatory milestone along with double-digit royalties on annual sales.
Cipla licenses cancer bispecific from China’s Sino Biopharma | PharmaVoice
